Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.20 per share a year ago.

Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates

Achieved Record Q2 2023 Total Net Revenues of $99.6 Million Achieved FIRDAPSE® 2023 Second Quarter Net Revenues of $64.9 Million, a 22% Increase YOY Achieved 2023 Second Quarter GAAP EPS Diluted of $0.33 Compared to $0.20 for Q2 2022 Achieved 2023 Second Quarter Non-GAAP EPS Diluted of $0.53 Compared to  $0.28 for Q2 2022 During Q3-23 Completed the Acquisition of the North American License for Vamorolone Submitted sNDA for FIRDAPSE Seeking to Increase the Maximum Indicated Dose to 100 mg per Day Completed the Integration of our FYCOMPA® Commercial and MSL Teams Raising Full Year 2023 Total Revenue Guidance of Between $380 Million and $390 Million Conference Call and Webcast to be Held on August 10, 2023, at 8:30 AM ET

Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update

ACM Research

Gray TV

Harmony Biosciences Holdings

International Money Express Inc.

Patrick Industries

Titan Machinery

Inherently, investors gravitate toward strong buy value stocks, in much the same way that audience members of a horror film might grip their armrests. As humans, we're basically hardwired – especially in the modern age – to respond positively to discounts.

7 ‘Strong Buy' Value Stocks You Should Be Loading Up On Now

Mr. McEnany will Continue to Serve as Catalyst's Non-Executive Chairman of the Board Following his Retirement Nationally Recognized Executive Recruitment Firm has been Retained to Initiate Search CORAL GABLES, Fla., July 25, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced that Patrick J.

Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End

The Company to Host a Conference Call and Webcast on August 10, 2023, at 8:30 AM ET The Company to Host a Conference Call and Webcast on August 10, 2023, at 8:30 AM ET

Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023

Vamorolone is a Promising Best-In-Class Dissociative Anti-Inflammatory Steroid Treatment for Duchenne Muscular Dystrophy

Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, July  19 , 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the closing of the exclusive license agreement for vamorolone in North America (NA) with Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) , announced on June   20 , 2023 [1].

Santhera Announces Closing of Exclusive North America License Agreement with Catalyst Pharmaceuticals for Vamorolone

The company reported record revenues of $85.4 million in 1Q 2023, a 98% YoY increase, and expects its 2Q, 3Q, and 4Q 2023 revenues to be higher than in 1Q. The company estimates about 10% of the patients that are taking 80 mg of FIRDAPSE per day may increase their doses to 100 mg after FDA's approval. It can happen in 3Q 2023, increasing CPRX's quarterly and annual revenues by $3.5 million and $14 million, respectively.

Catalyst Pharmaceuticals: Expecting Higher FIRDAPSE Revenues In A Year

This is a follow-up to my previous concerns about Catalyst Pharmaceuticals' over-dependence on FIRDAPSE, as expressed in my April 2023 article. I previously discussed Catalyst's acquisition of FYCOMPA in December 2022. The current article will revisit my thesis and discuss recent developments, including Catalyst's Q1 2023 performance.

Catalyst Pharmaceuticals: A New Catalyst Tilts The Scales - Just Barely

We check in on Catalyst Pharmaceuticals today as a lot has happened around the company since we last looked at it last summer. These include a major addition to the company's pipeline, challenges on the patent litigation front, and impressive organic sales growth from its primary drug asset. An updated investment analysis around Catalyst Pharmaceuticals follows in the paragraphs below.

Catalyst Pharmaceuticals: Cheap For A Reason

Andersons

Digital Turbine

Berry Petroleum Corp.

Ebix

iHuman

TaskUS

While acquiring little-known stocks can be a scary proposition, you should also realize that going with the predictable also has its risks. Fundamentally, anytime you enter the capital markets, you're taking risks.

7 Little-Known Stocks to Buy Now Before They Become the Next Big Thing

Investors need to pay close attention to Catalyst Pharmaceuticals (CPRX) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Catalyst Pharmaceuticals (CPRX) Stock?

Catalyst (CPRX) announces entering into a definitive agreement to acquire licensing rights in North America to Santhera's DMD treatment candidate, vamorolone, which is currently under FDA review.

Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera

Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023) for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease

Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held today at 1 4 : 3 0 CEST / 1 3 :30 BST / 08 :30 EDT.

Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Catalyst (CPRX) Is Considered a Good Investment by Brokers: Is That True?

Enerplus

Vipshop Hlds

Voyager Therapeutics

Algoma Steel Group

Dynavax Technologies

Momo

As a rule of thumb, you want to buy quality names in the market, which admittedly rules out several ideas for best stocks under $15 for June. It's not that cheap securities don't exist.

The 7 Best Stocks Under $15 to Buy in June 2023

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Wall Street Analysts See Catalyst (CPRX) as a Buy: Should You Invest?

Reaffirms Full Year 2023 Total Revenue Guidance of Between $375 Million and $385 Million Forecasts FIRDAPSE® 2023 Net Product Revenue Guidance of Between $245 Million and $255 Million, an Increase of 17% YoY Forecasts FYCOMPA® 2023 Net Product Revenue of Approximately $130 Million for 11 Months Reaffirms Full Year 2023 Non-GAAP Net Income Forecast of Between $195 Million and $205 Million CORAL GABLES, Fla., June 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today reported positive momentum for the second quarter of 2023 and reaffirmed its full-year 2023 total revenue guidance of between $375 million and $385 million, representing a 75% to 80% increase in total revenues compared to 2022.

Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023

CORAL GABLES, Fla., May 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced the appointment of Ms. Tamar Thompson to the Company's Board of Directors ("Board"), effective on May 25, 2023.

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

The market did not like the contents of Catalyst's latest earnings report. Overly-high expectations for its sales are to blame for its stock falling.

Down 19% in 1 Day, Is Catalyst Pharmaceuticals a Smart Contrarian Buy?

Brookfield Renewable Partners

Century Aluminum

MakeMyTrip

Warby Parker

Notable companies to have witnessed earnings acceleration as of now are Catalyst Pharmaceuticals (CPRX), Warby Parker (WRBY), MakeMyTrip (MMYT), Brookfield Renewable Partners (BEP) & Century Aluminum (CENX).

5 Stocks to Keep a Tab on for Solid Earnings Acceleration

Should You Invest in Catalyst (CPRX) Based on Bullish Wall Street Views?

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Patrick McEnany - Chairman, Chief Executive Officer Alicia Grande - Vice President, Chief Financial Officer Jeff Del Carmen - Chief Commercial Officer Steven Miller - Chief Operating Officer, Chief Scientific Officer Conference Call Participants Les Sulewski - Truist Securities Joe Catanzaro - Piper Sandler Pete Stavropoulos - Cantor Fitzgerald Operator Greetings and welcome to the Catalyst Pharmaceuticals first quarter 2023 financial results conference call. At this time, all participants are in a listen-only mode.

Catalyst Pharmaceuticals (CPRX) Q1 2023 Earnings Call Transcript

Catalyst (CPRX) reports mixed results for the first quarter, wherein earnings miss and revenues beat estimates. Fycompa sales boost revenues.

News for Catalyst Pharmaceuticals Stock (CPRX)